20 results about "Uremic toxins" patented technology

Described herein are bacterial compositions of modified probiotic bacteria having tolerance to one or more uremic toxins. Compositions of the disclosure can be used in the treatment of subjects having a condition or who are at risk of developing a condition associated with uremic toxin build up. Also provided herein are methods of preparing bacterial compositions of the disclosure.

The invention relates to a preparation method of a p-cresol sulfate (PCS) detection kit by using a chemiluminescence immunoassay technology, and particularly relates to a preparation method of a p-cresol sulfate (PCS) detection kit. P-cresol sulfate is a protein-bound uremic toxin in a human body, has small molecular weight and poor immunogenicity, and when a corresponding antibody is prepared, a hapten and a specific macromolecular carrier need to be coupled to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a sulfuric acid p-cresol hapten, preparation of a sulfuric acid p-cresol complete antigen and an anti-sulfuric acid p-cresol antibody, a method for measuring the concentration of sulfuric acid p-cresol, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a sulfuric acid p-cresol derivative. The p-cresol sulfate derivative disclosed by the invention has a structure as shown in a formula (I): # imgabs0 #, wherein R is-(CH2) n-COOH, and n is 4.

The invention relates to oat resistant starch as well as a preparation method and application thereof. The preparation method comprises the following steps: uniformly mixing oat powder with water, adjusting the pH value, carrying out alkali extraction, sieving, centrifuging, collecting precipitate, scraping a brown upper layer, washing a white part, drying, crushing and sieving to obtain oat starch; water is added into the obtained oat starch to prepare starch paste, the starch paste is cooled after gelatinization, the pH is adjusted, pullulanase is used for conducting enzymolysis on the oat starch, meanwhile, ultrasonic treatment is conducted, enzyme deactivation is conducted after enzymolysis is finished, then aging is conducted, drying, smashing and sieving are conducted, and the oat resistant starch is obtained. According to the method disclosed by the invention, an ultrasonic wave combined enzyme hydrolysis technology is used, and the enzymolysis of pullulanase is promoted by ultrasonic waves, so that the problems of low enzymolysis reaction efficiency, long enzymolysis time and the like in the process of preparing the resistant starch by an enzyme method are solved, and the content of the resistant starch in the oat starch is effectively increased from 6.12% to 36.15%. The oat resistant starch ORSU disclosed by the invention is beneficial to improving the renal function, reducing the generation of uremic toxins and delaying the CKD process.

The invention discloses a marker for diagnosing intestinal epithelial barrier injury induced by uremic toxin and application of the marker, and belongs to the technical field of biomedicine. Human colon cancer cells (Caco-2) are adopted to establish intestinal epithelial injury models under different urea treatment conditions, and the optimal concentration and time are screened through CCK-8 and immune blot. According to the present invention, RT-qPCR is adopted to detect the expression of lncRNANEAT1 and miR-122-5p, Westernblot and an immunofluorescence method are adopted to detect the expression of tight junction proteins Occludin, ZO-1 and Claudin-1, fluorescein sodium is adopted to detect the cell para-permeability of an intestinal epithelial injury model, and the combination of miR-122-5p with lncRNANEAT1 and Occludin is detected through bioinformatics analysis and dual-luciferase reporter gene analysis; the result shows that the lncRNANEAT1 can be used for protecting intestinal epithelial barrier injury induced by uremia toxin by regulating the miR-122-5p / Occludin axis. The discovery reveals an action mechanism of the lncRNANEAT1 in uremia toxin induced intestinal epithelial barrier injury, and provides a new thought and method for reducing complications of uremia patients and improving life quality.

The application discloses a high-loading MXene-encapsulated magnetic porous microcapsule for adsorption and a preparation method and application thereof, and belongs to the field of biomedical materials, and the preparation method comprises the following steps: in step one, a hydrogel precursor solution doped with magnetic nanoparticles is used as an external phase, and a MXene dispersion liquid is used as an inner phase, and a microfluidic coaxial electrospraying device is used to generate monodisperse core-shell droplets with uniform sizes; in step two, the monodisperse core-shell droplets prepared in step one are subjected to freezing pretreatment, and then are crosslinked with divalent metal ions, so that double gelation of the core layer and the shell layer is triggered, and hydrogel microspheres with a core-shell structure are obtained; and in step three, the hydrogel microspheres with the core-shell structure obtained in step two are subjected to freeze drying, and high-loading MXene-encapsulated magnetic porous microcapsules are obtained. The application has excellent blood compatibility and high adsorption capacity, and is outstanding in removing uremic toxins including creatinine, urea and uric acid, and is a kind of adsorbent which is both efficient and safe.

The application belongs to the technical field of biological medicine, and more particularly relates to application of a compound in preparation of a medicine for removing protein-bound uremic toxins in blood. The compound has a structural general formula shown in formula (I): wherein R1 is an aromatic heterocycle with a carbon number of 6-50, a benzenepropyl aromatic heterocycle with a carbon number of 6-50, or an aromatic hydrocarbon with a carbon number of 6-50; and R2 is a flavonoid group with a carbon number of 13-50, a polyphenol group, or a terpenoid group. Experiments show that the compound has a competitive replacement removal effect significantly better than that of the currently best replacement medicine, shikonin acid (LA), when the compound is used to remove protein-bound uremic toxins (PBUTs) such as IS and PCS by using a competitive replacement method, and the advantage is more obvious at a low concentration.

Metal-organic framework molecules with pyrene group-containing or biphenyl group-containing linkers for use in the removal of uremic toxins from biological samples that contain such toxins are provided. Also provided are methods for using the MOFs to remove uremic toxins from biological samples. The methods include hemodialysis of blood samples from patients suffering from a uremia-related disease, such as chronic kidney failure.

Metal-organic framework molecules with pyrene group-containing or biphenyl group-containing linkers for use in the removal of uremic toxins from biological samples that contain such toxins are provided. Also provided are methods for using the MOFs to remove uremic toxins from biological samples. The methods include hemodialysis of blood samples from patients suffering from a uremia-related disease, such as chronicap kidney failure.

The present invention relates to the field of biomedicine technology, and proposes a heparin-capturing uremic toxin adsorbent and a preparation method thereof. The raw materials of the adsorbent include styrene, acrylic acid, and divinylbenzene. Through the above technical solution, using polystyrene as the basic skeleton, by introducing polar monomers into the main structure, and activating the introduction of active groups such as hydroxyl and chloromethyl groups on the skeleton surface, a heparin-capturing adsorbent is prepared that can be rapidly cross-linked with heparin surface active groups through physical and chemical reactions to form an anti-coagulant surface. This solves the problem in the prior art that uremic toxin adsorbents can cause coagulation complications when used clinically.

The present invention provides a double-layer hollow fiber membrane for enclosing a hollow space through which blood flows and transporting uremic toxins and waste products from the blood to the outside, and a method for manufacturing the same. The double-layer hollow fiber membrane includes a first layer having first pores and a second layer having second pores. The first pores of the first layer and the second pores of the second layer are connected to each other, and the second pores are open pores connected to the outside. The double-layer hollow fiber membrane can remove uremic toxins with molecular sizes from blood while minimizing the loss of blood components and essential proteins due to the pores increasing in size from the first pores to the second pores.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a preparation method and application of uremia clearing extract. The preparation method comprises the following steps: mixing rheum officinale, astragalus membranaceus, white mulberry root-bark, radix sophorae flavescentis, codonopsis pilosula, bighead atractylodes rhizome, poria cocos, radix polygoni multiflori preparata, radix paeoniae alba, salvia miltiorrhiza, ligusticum wallichii, chrysanthemum, ginger processed pinellia, plantain herb, radix bupleuri and liquorice, and soaking in water to obtain a mixture; carrying out microwave extraction, filtering, collecting an extracting solution, and concentrating to obtain clear paste; and adding ethanol into the clear paste for alcohol precipitation, sequentially separating and purifying the supernatant through DM130 and LS-100 macroporous resins, collecting the eluent, and concentrating to obtain the traditional Chinese medicine composition. The preparation method of the uremia clearing extract is optimized, the extracting solution is obtained through microwave extraction, and then the specific purification process is adopted, so that the content of effective components such as paeoniflorin, astragaloside, stilbene glucoside and salvianolic acid B in the extract is obviously increased.

The present invention relates to antibodies or antigen-binding fragments thereof, specific for a uremic toxin(s), compositions comprising these antibodies or antigen-binding fragments, and methods of use thereof.

The invention relates to resistant starch, a recombination method and application of the resistant starch in nephropathy treatment, the resistant starch comprises oat, brown rice, raw potatoes, black beans, red beans, mung beans and retrogradation starch, the resistant starch is recombined by adopting extrusion puffing, microwave-enzyme synergistic recombination and pressure heating-freezing and thawing cycle recombination methods, and the resistant starch can be applied to prevention and / or treatment of diabetic nephropathy. And the recombinant resistant starch is not digested in small intestines and is fermented by intestinal flora to generate SCFA (Small Form Fatty Acid) such as butyric acid and propionic acid after reaching colon, so that the proliferation of bifidobacteria and lactic acid bacteria is promoted, and urease-producing bacteria are inhibited. The resistant starch can reduce generation of intestinal uremia toxins in vivo, reduce the situation that the intestinal uremia toxins enter blood circulation through intestinal-renal axes, and relieve oxidative stress and fibrosis of renal tubules. The SCFA promotes the secretion of GLP-1, improves the insulin sensitivity and reduces the damage of hyperglycemia to the kidney.

The invention discloses a traditional Chinese medicine compound preparation for treating nephrotic syndrome and a preparation method of the traditional Chinese medicine compound preparation, and belongs to the technical field of nephrotic syndrome treatment.The synbiotic microcapsule is prepared by compatibility of traditional Chinese medicines such as safflower, scutellaria baicalensis and perilla frutescens, and the synbiotic microcapsule is prepared by embedding traditional Chinese medicine extracts such as astragalus membranaceus and lily with lactobacillus acidophilus and bifidobacterium; and the wall material is prepared from mannose grafted meadowfoam seed extract, sodium alginate and fucoidin sulfate. The synbiotics microcapsule utilizes a Maillard reaction modified wall material to enhance gastric acid erosion resistance, realizes intestinal targeted colonization through mannose residues, protects probiotics, directionally releases traditional Chinese medicine active components, adjusts intestinal flora balance and inhibits uremia toxin generation. The traditional Chinese medicine components such as the safflower and the scutellaria baicalensis improve kidney blood circulation, relieve inflammatory response and regulate lipid metabolism by inhibiting an NF-kappa B channel, activating an AMPK channel and the like; the components such as the Chinese yam and the Chinese wolfberry can repair the permeability of glomerular basement membrane and improve the hypoproteinemia.

A method of performing dialysis includes: recirculating a dialysis fluid from a patient or a dialyzer for at least two cycles, each cycle contacting the dialysis fluid first with a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; storing the recirculated dialysis fluid in a storage container; and transferring the dialysis fluid from the storage container to the patient or the dialyzer. In one example, the zirconium phosphate layer and the at least one of the urease layer, the zirconium oxide layer, or the carbon layer is provided by a sorbent cartridge.

The present invention provides an activated carbon adsorbent for oral administration, wherein the activated carbon adsorbent is in the form of particles obtained by carbonization and subsequent activation of poly(styrene-co-divinylbenzene) particles, wherein the poly(styreneco-divinylbenzene) particles are macroporous and have a moisture content of from about 5 wt% to about 60 wt% relative to the total mass of the poly(styrene-co- divinylbenzene) particles. The present invention also provides an activated carbon adsorbent for oral administration, wherein the activated carbon adsorbent is in the form of particles, comprises micropores and mesopores, and has a total surface area of at least about 1000 m2 / g and a total pore volume of at least about 1 cm3 / g, wherein at least about 50% of the total pore volume is formed by the micropores, and at least about 20% of the total pore volume is formed by the mesopores. The present disclosure also provides a pharmaceutical composition comprising an activated carbon adsorbent of the present invention, and an in vitro method of removing one or more uremic toxins from a fluid using an activated carbon adsorbent of the present invention. As disclosed herein, the activated carbon adsorbents also find utility in the treatment of a renal disease or a liver disease.

The present invention relates to compositions for reducing or avoiding uremic toxin accumulation in cardiovascular metabolism or neurodegenerative disorders, in particular compositions comprising probiotics, prebiotics (carbohydrates or fibres) and lipids.

The application provides a method and application for detecting protein-bound uremic toxins, which comprises the following steps: mixing a blood sample and a protein precipitation extractant, centrifugally separating to obtain supernatant, mixing the supernatant and the protein precipitation extractant, centrifugally separating, filtering the treated supernatant to obtain a sample solution to be detected; preparing a standard solution of each sample to be detected, mixing the standard solutions of all the samples to be detected, and preparing a plurality of mixed standard solutions with different concentrations of the samples to be detected; performing high performance liquid chromatography on the mixed standard solutions to draw a standard curve between the concentration and the peak area of each sample to be detected, performing high performance liquid chromatography on the sample solution to be detected to obtain the determination peak area of each sample to be detected, and calculating the content of each sample to be detected according to the corresponding standard curve. The application solves the problems of low detection sensitivity and difficulty in accurate detection of the existing detection methods.

The present invention relates to a sea urchin-derived peptide and a use thereof and more specifically, to a use of the sea urchin-derived peptide for preventing or treating a disease associated with the V1B receptor of Echinotocin, which is a peptide derived from sea urchins. The Echinotocin according to the present invention was found to have an effect of inducing activation of the V1B receptor, which is a type of vasopressin receptors. The V1B receptor, which is a vasopressin receptor, exists in the anterior pituitary gland and the hippocampus CA2 region and is known to increase intracellular calcium concentration and to be involved in a response to stress and sociality. Therefore, the Echinotocin according to the present invention can find various applications in the field of preventing, alleviating, or treating V1B receptor-related diseases.

The present invention relates to a composition for preventing, ameliorating, or treating kidney and liver diseases, comprising a complex (NEPROBIN) of Ganoderma lucidum extract and Robinia pseudoacacia flower extract as an active ingredient. The complex provided from the present invention exhibits excellent effects in preventing kidney damage, maintaining kidney function, and regenerating kidney tissue by means of inhibition of NO production, reduction in cytokine (TNF-a) and Crp gene expression, increase in glutathione, reduction in ROS production, and increase in uremic toxin excretion, and exhibits excellent effects in preventing liver damage and improving liver function by means of inhibition of NO production, reduction in cytokine (IL6) and MCP1 and CXCL1 gene expression, increase in glutathione, suppression of expression of fibrosis markers (ACTA2, Vim, COL3A1) of hepatic stellate cells, restoration of GSH in liver tissue, increase in antioxidant enzyme activity, and suppression of expression of antiinflammatory- and antifibrotic-related genes and proteins, and thus, the complex is applicable as a pharmaceutical composition for preventing or treating kidney and / or liver diseases, and as a health functional food and food composition for preventing or ameliorating liver diseases.